United Therapeutics (UTHR) Equity Average (2010 - 2026)

United Therapeutics has disclosed Equity Average across 17 years of filings, most recently posting $6.5 billion for Q1 2026.

• Equity Average for Q1 2026 came in at $6.5 billion, down 1.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.5 billion (down 1.92% YoY), and the FY2025 annual result was $6.8 billion, up 8.94% from the prior year.
• Equity Average came in at $6.5 billion for Q1 2026 at United Therapeutics, down from $6.8 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $7.0 billion in Q2 2025 to a low of $4.1 billion in Q1 2022.
• The 5-year median for Equity Average is $5.7 billion (2024), against an average of $5.7 billion.
• Across the five-year window, Equity Average advanced 26.69% in 2025 and retreated 1.92% in 2026, its largest moves.
• United Therapeutics' Equity Average stood at $4.7 billion in 2022, then rose by 24.98% to $5.8 billion in 2023, then gained by 7.25% to $6.3 billion in 2024, then increased by 9.1% to $6.8 billion in 2025, then dropped by 5.03% to $6.5 billion in 2026.
• The last three Equity Average figures came in at $6.5 billion (Q1 2026), $6.8 billion (Q4 2025), and $6.9 billion (Q3 2025), per Business Quant data.